Kardigan, a heart health company modernizing cardiovascular drug development, launched with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve. Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death. On friday he announced that he and myokardia’s executive team have raised $300 million for a new heart disease company, kardigan, that will focus on targeted drugs for heart disease. The company’s proprietary cardiac intelligence model aims to personalize treatments, increase clinical efficiency, and accelerate drug development
WATCH
